Chemotherapy administration directly into the fourth ventricle in a nonhuman primate model

Laboratory investigation

View More View Less
  • 1 Departments of Neurological Surgery and
  • 2 Epidemiology and Public Health, and
  • 3 Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine;
  • 4 Division of Neurosurgery, Miami Children's Hospital, Miami, Florida;
  • 5 MPI Research, Mattawan, Michigan; and
  • 6 Neurosurgery, University of Mississippi Medical Center, Jackson, Mississippi
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

Object

The authors hypothesized that chemotherapy infusions directly into the fourth ventricle might potentially play a role in treating malignant fourth ventricular tumors. The study tested the safety and pharmacokinetics of short- and long-term infusions of methotrexate into the fourth ventricle in a new nonhuman primate model.

Methods

Six rhesus monkeys underwent posterior fossa craniectomy and catheter insertion into the fourth ventricle. In Group I (3 animals), catheters were externalized, and lumbar drain catheters were placed simultaneously to assess CSF distribution after short-term methotrexate infusions. In 2 animals, methotrexate (0.5 mg) was infused into the fourth ventricle daily for 5 days. Serial CSF and serum methotrexate levels were measured. The third animal had a postoperative neurological deficit, and the experiment was aborted prior to methotrexate administration. In Group II (3 animals), catheters were connected to a subcutaneously placed port for subsequent long-term methotrexate infusions. In 2 animals, 4 cycles of intraventricular methotrexate, each consisting of 4 daily infusions (0.5 mg), were administered over 8 weeks. The third animal received 3 cycles, and then the experiment was terminated due to self-inflicted wound breakdown. All animals underwent detailed neurological evaluations, MRI, and postmortem histological analysis.

Results

No neurological deficits were noted after intraventricular methotrexate infusions. Magnetic resonance images demonstrated catheter placement within the fourth ventricle and no signal changes in the brainstem or cerebellum. Histologically, two Group I animals, one of which did not receive methotrexate, had several small focal areas of brainstem injury. Two Group II animals had a small (≤ 1-mm) focus of axonal degeneration in the midbrain. Intraventricular and meningeal inflammation was noted in 4 animals after methotrexate infusions (one from Group I and all three from Group II). In all Group II animals, inflammation extended minimally into brainstem parenchyma. Serum methotrexate levels were undetectable or negligible in both groups, ranging from 0.00 to 0.06 μmol/L. In Group I, the mean peak methotrexate level in fourth ventricle CSF exceeded that in the lumbar CSF by greater than 10-fold. Statistically significant differences between fourth ventricle and lumbar AUC (area under the concentration-time curve) were detected at peaks (p = 0.04) but not at troughs (p = 0.50) or at all time collection points (p = 0.12). In Group II, peak fourth ventricle CSF methotrexate levels ranged from 84.62 to 167.89 μmol/L (mean 115.53 ± 15.95 μmol/L [SD]). Trough levels ranged from 0.06 to 0.55 μmol/L (mean 0.22 ± 0.13 μmol/L).

Conclusions

Methotrexate can be infused into the fourth ventricle in nonhuman primates without clinical or radiographic evidence of injury. Observed inflammatory and other histological changes had no clinical correlate. This approach may have pharmacokinetic advantages over current treatment paradigms. Further experiments are warranted to determine if fourth ventricular chemotherapy infusions may benefit patients with malignant fourth ventricular tumors.

Abbreviations used in this paper:AUC = area under the concentration-time curve; IACUC = Institutional Animal Care and Use Committee.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

Address correspondence to: David I. Sandberg, M.D., Division of Neurosurgery, Miami Children's Hospital, Ambulatory Care Building, Suite 3109, 3215 SW 62nd Avenue, Miami, Florida 33155. email: david.sandberg@mch.com.

Please include this information when citing this paper: DOI: 10.3171/2012.1.PEDS11410.

  • 1

    Balis FM, , Blaney SM, , McCully CL, , Bacher JD, , Murphy RF, & Poplack DG: Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration. Cancer Chemother Pharmacol 45:259264, 2000

    • Search Google Scholar
    • Export Citation
  • 2

    Bleyer WA, , Pizzo PA, , Spence AM, , Platt WD, , Benjamin DR, & Kolins CJ, : The Ommaya reservoir: newly recognized complications and recommendations for insertion and use. Cancer 41:24312437, 1978

    • Search Google Scholar
    • Export Citation
  • 3

    Chamberlain MC, , Kormanik PA, & Barba D: Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 87:694699, 1997

    • Search Google Scholar
    • Export Citation
  • 4

    DeAngelis LM: Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 38:245252, 1998

  • 5

    Fleischhack G, , Reif S, , Hasan C, , Jaehde U, , Hettmer S, & Bode U: Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. Br J Cancer 84:14531459, 2001

    • Search Google Scholar
    • Export Citation
  • 6

    Hryniuk WM, & Bertino JR: Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. J Clin Invest 48:21402155, 1969

    • Search Google Scholar
    • Export Citation
  • 7

    Jacobs A, , Clifford P, & Kay HE: The Ommaya reservoir in chemotherapy for malignant disease in the CNS. Clin Oncol 7:123129, 1981

  • 8

    Kaatsch P, , Rickert CH, , Kühl J, , Schüz J, & Michaelis J: Population-based epidemiologic data on brain tumors in German children. Cancer 92:31553164, 2001

    • Search Google Scholar
    • Export Citation
  • 9

    Macdonald DR: Neurologic complications of chemotherapy. Neurol Clin 9:955967, 1991

  • 10

    Obbens EA, , Leavens ME, , Beal JW, & Lee YY: Ommaya reservoirs in 387 cancer patients: a 15-year experience. Neurology 35:12741278, 1985

  • 11

    Rubinstein LJ, , Herman MM, , Long TF, & Wilbur JR: Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer 35:291305, 1975

    • Search Google Scholar
    • Export Citation
  • 12

    Ruggiero A, , Conter V, , Milani M, , Biagi E, , Lazzareschi I, & Sparano P, : Intrathecal chemotherapy with antineoplastic agents in children. Paediatr Drugs 3:237246, 2001

    • Search Google Scholar
    • Export Citation
  • 13

    Rutkowski S, , Bode U, , Deinlein F, , Ottensmeier H, , Warmuth-Metz M, & Soerensen N, : Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352:978986, 2005

    • Search Google Scholar
    • Export Citation
  • 14

    Sandberg DI, , Bilsky MH, , Souweidane MM, , Bzdil J, & Gutin PH: Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 47:4955, 2000

    • Search Google Scholar
    • Export Citation
  • 15

    Sandberg DI, , Crandall KM, , Koru-Sengul T, , Padgett KR, , Landrum J, & Babino D, : Pharmacokinetic analysis of etoposide distribution after administration directly into the fourth ventricle in a piglet model. J Neurooncol 97:2532, 2010

    • Search Google Scholar
    • Export Citation
  • 16

    Sandberg DI, , Crandall KM, , Petito CK, , Padgett KR, , Landrum J, & Babino D, : Chemotherapy administration directly into the fourth ventricle in a new piglet model. Laboratory investigation. J Neurosurg Pediatr 1:373380, 2008

    • Search Google Scholar
    • Export Citation
  • 17

    Sandberg DI, , Solano J, , Petito CK, , Mian A, , Mou C, & Koru-Sengul T, : Safety and pharmacokinetic analysis of methotrexate administered directly into the fourth ventricle in a piglet model. J Neurooncol 100:397406, 2010

    • Search Google Scholar
    • Export Citation
  • 18

    Shapiro WR, , Posner JB, , Ushio Y, , Chemik NL, & Young DF: Treatment of meningeal neoplasms. Cancer Treat Rep 61:733743, 1977

  • 19

    Shapiro WR, , Young DF, & Mehta BM: Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293:161166, 1975

    • Search Google Scholar
    • Export Citation
  • 20

    Slavc I, , Schuller E, , Czech T, , Hainfellner JA, , Seidl R, & Dieckmann K: Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination. J Neurooncol 38:213218, 1998

    • Search Google Scholar
    • Export Citation
  • 21

    Slavc I, , Schuller E, , Falger J, , Günes M, , Pillwein K, & Czech T, : Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors. J Neurooncol 64:239247, 2003

    • Search Google Scholar
    • Export Citation
  • 22

    Yoshimura J, , Nishiyama K, , Mori H, , Takahashi H, & Fujii Y: Intrathecal chemotherapy for refractory disseminated medulloblastoma. Childs Nerv Syst 24:581585, 2008

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 450 186 6
Full Text Views 82 2 0
PDF Downloads 58 1 0
EPUB Downloads 0 0 0